论文部分内容阅读
目的研究胃癌患者新辅助化疗前后Ki-67及β-catenin的表达及意义。方法选取胃癌患者100例,给予胃癌患者新辅助化疗,观察Ki-67和β-catenin不同表达情况下患者的预后情况,并对新辅助化疗的胃癌患者的预后情况进行Cox比例风险回归分析。结论治疗前不同性别、年龄、病程的患者Ki-67和β-catenin比较,差异无统计学意义(P﹥0.05);治疗前不同肿瘤分期及分化程度间Ki-67和β-catenin差异有统计学意义(P﹤0.05)。Ki-67阳性表达患者疗效较Ki-67阴性表达患者差(P﹤0.05),β-catenin阳性表达患者疗效也较β-catenin阴性表达患者差(P﹤0.05)。Cox比例风险回归分析结果显示Ki-67、β-catenin是影响胃癌患者预后的独立危险因素之一。结论Ki-67、β-catenin的表达变化可能作为指导胃癌新辅助化疗的重要指标之一,值得探讨。
Objective To study the expression of Ki-67 and β-catenin in patients with gastric cancer before and after neoadjuvant chemotherapy. Methods 100 patients with gastric cancer were selected. Neoadjuvant chemotherapy was given to patients with gastric cancer. The prognosis of patients with different expression of Ki-67 and β-catenin was observed. Cox proportional hazards regression analysis was performed on the prognosis of gastric cancer patients receiving neoadjuvant chemotherapy. Conclusions Ki-67 and β-catenin in patients with different gender, age and course of disease before treatment have no significant difference (P> 0.05). The differences of Ki-67 and β-catenin between different tumor stages and differentiation before treatment are statistically Significance (P <0.05). The therapeutic effect of Ki-67 positive patients was worse than that of Ki-67 negative patients (P <0.05). The patients with positive β-catenin expression also had worse curative effect than those with negative β-catenin expression (P <0.05). Cox proportional hazards regression analysis showed that Ki-67, β-catenin is an independent risk factor for gastric cancer prognosis. Conclusion The expression changes of Ki-67 and β-catenin may be one of the important indexes to guide the neoadjuvant chemotherapy of gastric cancer, which is worth discussing.